This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 1g | $199 | Check With Us |
| 2g | $330 | Check With Us |
| 5g | $550 | Check With Us |
: Cat #: V2000 CAS #: 71939-50-9 Purity ≥ 98%
Description: Dihydroartemisinin (DHA) is a semi-synthetic derivative and active metabolite of artemisinin that is isolated from the traditional Chinese herb Artemisia annua. Dihydro Artemisinin is an active antimalarial metabolite. It is also the main metabolite of the following substances such as Artemisinin, Arteether, Artemether, Artesunate.
References: [1]. Hu W, et al. Dihydroartemisinin induces autophagy by suppressing NF-κB activation. Cancer Lett. 2014 Feb 28;343(2):239-48.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 284.35 |
|---|---|
| Molecular Formula | C15H24O5 |
| CAS No. | 71939-50-9 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: > 10 mMr |
| Water: N/Ar | |
| Ethanol: N/A | |
| SMILES Code | O[C@@H]1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1 |
| Synonyms | β-Dihydroartemisinin; DHA; Alaxin; Cotecxin; Cotexin; DHQHS 2; Dihydroartemisinine; Dihydroqinghaosu |
| Protocol | In Vitro | Dihydroartemisinin (DHA) is an antimalarial agent. Dihydroartemisinin treatment effectively up-regulates the cytosolic RelA/p65 protein level and down-regulates the nuclear RelA/p65 protein level. Dihydroartemisinin blocks the nuclear translocation of RelA/p65 from the cytosol rather than suppressing RelA/p65 protein synthesis. Dihydroartemisinin induces autophagy in RPMI 8226 cells. Dihydroartemisinin suppresses NF-κB activation in RPMI 8226 cells. The NF-κB Dihydroartemisinin -binding activity is examined by EMSA assay. RPMI 8226 cells are exposed to various concentrations of Dihydroartemisinin (10, 20 and 40 μM) for 12 h, and TNF-α is introduced as a positive control for NF-κB activation. Dihydroartemisinin suppresses NF-κB activation in a dose-dependent manner in contrast with TNF-α. Dihydroartemisinin (DHA) can enhance the anti-tumor effect of photodynamic therapy (PDT) on esophageal cancer cells, and cell viability is investigated using the MTT assay. Eca109 and Ec9706 cells are treated with Dihydroartemisinin (80 μM), PDT (25 and 20 J/cm2, respectively) or their combination. Single treatment with Dihydroartemisinin or PDT causes a 37±5% or 34±6% reduction in viability in Eca109 cells and a 33±7% or 34±6% reduction in Ec9706 cells, respectively. However, when PDT is combined with Dihydroartemisinin, the cell viability is reduced 59±6% or 61±7% in the cell lines, respectively. |
|---|---|---|
| In Vivo | Single oral doses of Dihydroartemisinin (at 200, 300, 400 or 600 mg/kg), given once on each of day 6-8 post-infection, reduce total-worm burdens by 69.2%-90.6% and female-worm burdens by 62.2%-92.2%, depending on dosage in the first experiment. Similar treatments given on day 34-36 post-infection reduce total-worm burdens by 73.9%-85.5% and female-worm burdens by 83.8%-95.3%. |
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 3.5168 mL | 17.5840 mL | 35.1679 mL | 70.3359 mL |
| 5mM | 0.7034 mL | 3.5168 mL | 7.0336 mL | 14.0672 mL |
| 10mM | 0.3517 mL | 1.7584 mL | 3.5168 mL | 7.0336 mL |
| 20mM | 0.1758 mL | 0.8792 mL | 1.7584 mL | 3.5168 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.